Efficacy and safety comparison of Hydroxychloroquine Sulfate and Igura-timod in the treatment of Sj?gren syndrome
Objective To compare the efficacy and safety of Hydroxychloroquine Sulfate and Iguratimod in the treatment of Sjögren syndrome(SS).Methods Ninety SS patients admitted to the Department of Rheumatology and Immunology,Jiu Jiang NO.1 People's Hospital from April 2019 to May 2021 were selected as the research objects and divided into group A(n=45)and group B(n=45)according to random number table method.Group A was treated with Hydroxychloroquine Sulfate and group B was treated with Iguratimod for 3 months.The efficacy,rheumatoid factor(RF),erythrocyte sedimentation rate(ESR),immunoglobulin G(IgG),platelet count(PLT),inflammatory markers(interleukin-6[IL-6],tumor necrosis factor-α[TNF-α],intercellular adhesion molecule-1[ICAM-1])and adverse reactions were compared between the two groups.Re-sults The total effective rate of group B was higher than that of group A,the difference was statistically significant(P＜0.05).After treatment,the RF,ESR and IgG levels in group B were lower than those in group A,and the PLT level was higher than that in group A,the differences were statistically significant(P＜0.05).The levels of IL-6,TNF-α and ICAM-1 in group B after treatment were lower than those in group A,and the differences were statistically significant(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Compared with Hydroxychloroquine,Iguratimod has a better effect in the treatment of SS,which can reduce IgG and RF levels,inhibit B cell activity,increase PLT levels,and alleviate inflammatory response,with good safety.
万方数据
维普
